Drug Integrity Articles & Analysis: Older
24 news found
Customization for Personalized Medicine: Antibodies are tailored to individual patient profiles, enhancing the potential for personalized medicine and increasing treatment efficacy while minimizing side effects. 5. Integration with Protein Drug Design: CD ComputaBio's platform seamlessly integrates Antibody De Novo Design with Protein ...
Additionally, data from the PARIS Test is used to accelerate drug discovery by identifying optimal patient populations for specific drugs. About SEngine Precision Medicine SEngine Precision Medicine Inc. is revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D tumor models and engaging in drug discovery. ...
August 29, 2022, Baltimore, MD and Indianapolis, IN – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, today announced the launch of a partnership with Helix BioStructures, a pharmaceutical-biotech contract research organization that provides high-quality, integrated drug ...
“The power of SEngine’s PARIS® platform to improve patient outcomes by providing oncologists individual drug effectiveness rankings as well as the innovation of new drugs will continue to propel SEngine ...
CD BioSciences, a leading customer-focused biotechnology company based in New York, introduces new GPCR purification services to support and facilitate GPCR research and drug development. CD BioSciences has built an unparalleled GPCR purification platform to provide the most reliable service for researchers. ...
Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. ...
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design and Sygnature Discovery, a leading integrated drug discovery CRO headquartered in Nottingham, UK, with expertise across a range of therapeutic and biological target classes today announced a collaboration agreement in AI for new drug design. Under ...
ByIktos
Packaging is another factor that decides the stability and integrity of drugs. Except for the role as an excipient producer and supplier, the US-based CRO company CD Formulation today announces that it newly launches a wide range of pharmaceutical packaging services, providing support throughout the whole process of packaging design, from material selection to ...
Logica leverages Valo’s AI-powered Opal Computational Platform and Charles River’s leading preclinical expertise, providing clients with transformed drug discovery with a single integrated offering seamlessly translating targets to candidate nomination. ...
Creative Biostructure Drug Discovery, a sub-brand of Creative Biostructure, whose mission is to accelerate the preclinical development of innovative drugs through structural insight, recently established a MagHelix™ CADD Platform, a comprehensive platform for new drug discovery that integrates a variety of computer ...
” About PARIS® Test The PARIS® Test is a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with drug sensitivity testing of patient-derived live cells combined with robotics and proprietary algorithms. ...
The Test pre-screens a broad panel of cancer drugs on live patient-derived tumor cells with a battery of oncology drugs selected from a menu of targeted and less-toxic medications. ...
As part of Lonza's continued investment in China, a new drug product fill and finish manufacturing line will be installed at its Guangzhou (CN) site The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product ...
As part of Lonza's continued investment in China, a new drug product fill and finish manufacturing line will be installed at its Guangzhou (CN) site The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product ...
With the addition of the Cube and VenSure technologies to the already clinically proven portfolio of localized drug delivery products, PROPEL® (mometasone furoate) and SINUVA® (mometasone furoate) sinus implants, the company now offers a more comprehensive and integrated set of treatment solutions for physicians and their patients across the continuum of ...
Details related to the poster presentation are as follows: Title: A cancer organogram test as a guide for oncology treatments in solid tumors: an analysis of 628 tests in 419 patients First Author: Astrid Margossian, MD, PhD Senior Author: Carla Grandori, MD, PhD Abstract Number: 2602 Poster Session: Developmental Therapeutics— Immunotherapy About PARIS® Test The PARIS® ...
Experienced machine learning and engineering leader Andrew Watson joins Healx from technology giant Dyson as VP of Artificial Intelligence. In his new role, Andrew will deepen the investment in Healx’s artificial intelligence team and scale Healx’s technical capabilities in order to identify and progress more novel treatments for rare diseases. Andrew’s appointment reinforces ...
Establishes Thermo Fisher as a global leader in the attractive and high growth clinical research services industry Adds highly complementary services for the company's fastest growing end market Offers both meaningful cost and revenue synergies which will further accelerate growth Expected to be immediately and significantly accretive to Adjusted Earnings Per Share (EPS)¹ after close ...
Ibrutinib is an FDA approved drug only used to treat mantle cell lymphoma and chronic lymphocytic leukemia. ...
(Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that the company will present Phase 2 results from the LANTERN study for LYR-210, the company’s lead product ...